bioMérieux Gains CE Mark for its Vidas Tests for Chikungunya Virus Diagnosis

French in vitro diagnostics company bioMérieux has received a CE mark for its automated tests to diagnose Chikungunya virus infection using its Vidas immunoassay instruments.

The Vidas Anti-Chikungunya IgM (immunoglobulin M) and Anti-Chikungunya IgG (immunoglobulin G) automated tests can detect the infection during the acute and chronic phases.

The tests can differentiate between Chikungunya and other similar syndromes caused by infections, such as dengue or malaria, the company said.

The mosquito-borne virus is a tropical pathogen that has been spreading to temperate regions, including North America and Europe.